Movement Alert｜Veeva Rises 5.64% in After-Hours Trading, Q2 Earnings and Revenue Beat Estimates with Raised Full-Year Guidance

Market Focus

1 hour ago

On August 27, Veeva rose 5.64% in after-hours trading, trading at $258.46/share, with turnover of $9.93 million.

The company reported fiscal Q2 adjusted EPS of $2.35, beating the consensus estimate of $2.22 by 5.86% and representing an 18.09% year-over-year increase. Revenue came in at $927.96 million, surpassing the $905.28 million estimate. Additionally, Veeva raised its full-year fiscal 2027 adjusted EPS guidance to approximately $9.21, above the FactSet estimate of $9.06, reflecting continued confidence in growth momentum.

The strong results come amid accelerating Vault CRM adoption among top pharmaceutical companies. Biogen, Regeneron, and Eli Lilly have all committed to deploying the platform globally, bringing Veeva's commitments to 13 of the top 20 pharma companies versus six for Salesforce. Prior to the earnings release, Guggenheim and Stifel raised their price targets to $276 and $275 respectively, both maintaining Buy ratings.

(The above content is based on publicly available market information, generated by a program or algorithm, and is intended solely as a stock movement alert. It does not constitute investment advice or a basis for trading decisions.)

Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.

Most Discussed

1
2
3
4
5
6
7
8
9
10

{"basename":"","ssrTDKData":{"titleTemplate":"%s - Tiger Brokers","title":"Easy breezy. No more feesies.","description":"Tiger Trade is a mobile trading app offering real time data, low commission fees and a free demo account. Download now to start investing in ETFs, options and the global share market.","keywords":"Tiger Brokers,U.S. stock trading,Hong Kong stock trading,trading U.S. stocks,stock information,stock prices,U.S. stock quotes,U.S. stock trading,Hong Kong stock trading,IPO trading,buying U.S. stocks,global investment","social":{"ogDescription":"Tiger Trade is a mobile trading app offering real time data, low commission fees and a free demo account. Download now to start investing in ETFs, options and the global share market.","ogImage":"https://c1.itigergrowtha.com/portal5/static/media/og-logo.0a0bd8dc.png","ogUrl":"https://nz.tigermarketb.com/news/1187993950"},"companyName":"Tiger Brokers"},"pageData":{"isMobile":false,"isTiger":false,"isTTM":true,"region":"NZL","license":"TBKIWI","edition":"fundamental"},"isCrawlerRequest":true,"__swrFallback__":{"@#url:\"https://stock-news.skytigris.cn/v3/news\",params:#id:\"1187993950\",edition:\"fundamental\",auth_exemption:1,,,undefined,":{"share":"https://ttm.financial/m/news/1187993950?lang=en_US&edition=fundamental","thumbnail":"","is_english":true,"pubTime":"2026-08-27 04:13","share_image_url":"https://static.laohu8.com/e9f99090a1c2ed51c021029395664489","id":"1187993950","market":"us","top_or_hot":-1,"title":"Movement Alert｜Veeva Rises 5.64% in After-Hours Trading, Q2 Earnings and Revenue Beat Estimates with Raised Full-Year Guidance","media":"Market Focus","content":"<p><p>On August 27, Veeva rose 5.64% in after-hours trading, trading at $258.46/share, with turnover of $9.93 million.</p><p>The company reported fiscal Q2 adjusted EPS of $2.35, beating the consensus estimate of $2.22 by 5.86% and representing an 18.09% year-over-year increase. Revenue came in at $927.96 million, surpassing the $905.28 million estimate. Additionally, Veeva raised its full-year fiscal 2027 adjusted EPS guidance to approximately $9.21, above the FactSet estimate of $9.06, reflecting continued confidence in growth momentum.</p><p>The strong results come amid accelerating Vault CRM adoption among top pharmaceutical companies. Biogen, Regeneron, and Eli Lilly have all committed to deploying the platform globally, bringing Veeva's commitments to 13 of the top 20 pharma companies versus six for Salesforce. Prior to the earnings release, Guggenheim and Stifel raised their price targets to $276 and $275 respectively, both maintaining Buy ratings.</p><p>(The above content is based on publicly available market information, generated by a program or algorithm, and is intended solely as a stock movement alert. It does not constitute investment advice or a basis for trading decisions.)</p></p>","source":null,"html":"<!DOCTYPE html>\n<html>\n<head>\n<meta http-equiv=\"Content-Type\" content=\"text/html; charset=utf-8\" />\n<meta name=\"viewport\" content=\"width=device-width,initial-scale=1.0,minimum-scale=1.0,maximum-scale=1.0,user-scalable=no\"/>\n<meta name=\"format-detection\" content=\"telephone=no,email=no,address=no\" />\n<title>Movement Alert｜Veeva Rises 5.64% in After-Hours Trading, Q2 Earnings and Revenue Beat Estimates with Raised Full-Year Guidance</title>\n<style type=\"text/css\">\na,abbr,acronym,address,applet,article,aside,audio,b,big,blockquote,body,canvas,caption,center,cite,code,dd,del,details,dfn,div,dl,dt,\nem,embed,fieldset,figcaption,figure,footer,form,h1,h2,h3,h4,h5,h6,header,hgroup,html,i,iframe,img,ins,kbd,label,legend,li,mark,menu,nav,\nobject,ol,output,p,pre,q,ruby,s,samp,section,small,span,strike,strong,sub,summary,sup,table,tbody,td,tfoot,th,thead,time,tr,tt,u,ul,var,video{ font:inherit;margin:0;padding:0;vertical-align:baseline;border:0 }\nbody{ font-size:16px; line-height:1.5; color:#999; background:transparent; }\n.wrapper{ overflow:hidden;word-break:break-all;padding:10px; }\nh1,h2{ font-weight:normal; line-height:1.35; margin-bottom:.6em; }\nh3,h4,h5,h6{ line-height:1.35; margin-bottom:1em; }\nh1{ font-size:24px; }\nh2{ font-size:20px; }\nh3{ font-size:18px; }\nh4{ font-size:16px; }\nh5{ font-size:14px; }\nh6{ font-size:12px; }\np,ul,ol,blockquote,dl,table{ margin:1.2em 0; }\nul,ol{ margin-left:2em; }\nul{ list-style:disc; }\nol{ list-style:decimal; }\nli,li p{ margin:10px 0;}\nimg{ max-width:100%;display:block;margin:0 auto 1em; }\nblockquote{ color:#B5B2B1; border-left:3px solid #aaa; padding:1em; }\nstrong,b{font-weight:bold;}\nem,i{font-style:italic;}\ntable{ width:100%;border-collapse:collapse;border-spacing:1px;margin:1em 0;font-size:.9em; }\nth,td{ padding:5px;text-align:left;border:1px solid #aaa; }\nth{ font-weight:bold;background:#5d5d5d; }\n.symbol-link{font-weight:bold;}\n/* header{ border-bottom:1px solid #494756; } */\n.title{ margin:0 0 8px;line-height:1.3;color:#ddd; }\n.meta {color:#5e5c6d;font-size:13px;margin:0 0 .5em; }\na{text-decoration:none; color:#2a4b87;}\n.meta .head { display: inline-block; overflow: hidden}\n.head .h-thumb { width: 30px; height: 30px; margin: 0; padding: 0; border-radius: 50%; float: left;}\n.head .h-content { margin: 0; padding: 0 0 0 9px; float: left;}\n.head .h-name {font-size: 13px; color: #eee; margin: 0;}\n.head .h-time {font-size: 11px; color: #7E829C; margin: 0;line-height: 11px;}\n.small {font-size: 12.5px; display: inline-block; transform: scale(0.9); -webkit-transform: scale(0.9); transform-origin: left; -webkit-transform-origin: left;}\n.smaller {font-size: 12.5px; display: inline-block; transform: scale(0.8); -webkit-transform: scale(0.8); transform-origin: left; -webkit-transform-origin: left;}\n.bt-text {font-size: 12px;margin: 1.5em 0 0 0}\n.bt-text p {margin: 0}\n</style>\n</head>\n<body>\n<div class=\"wrapper\">\n<header>\n<h2 class=\"title\">\nMovement Alert｜Veeva Rises 5.64% in After-Hours Trading, Q2 Earnings and Revenue Beat Estimates with Raised Full-Year Guidance\n</h2>\n\n<h4 class=\"meta\">\n\n\n<a class=\"head\" href=\"https://laohu8.com/wemedia/1054767329\">\n\n\n<div class=\"h-thumb\" style=\"background-image:url(https://static.tigerbbs.com/51943b2858f75e05ca2ebb144b4e626a);background-size:cover;\"></div>\n\n<div class=\"h-content\">\n<p class=\"h-name\">Market Focus </p>\n<p class=\"h-time\">2026-08-27 04:13</p>\n</div>\n\n</a>\n\n\n</h4>\n\n</header>\n<article>\n<p><p>On August 27, Veeva rose 5.64% in after-hours trading, trading at $258.46/share, with turnover of $9.93 million.</p><p>The company reported fiscal Q2 adjusted EPS of $2.35, beating the consensus estimate of $2.22 by 5.86% and representing an 18.09% year-over-year increase. Revenue came in at $927.96 million, surpassing the $905.28 million estimate. Additionally, Veeva raised its full-year fiscal 2027 adjusted EPS guidance to approximately $9.21, above the FactSet estimate of $9.06, reflecting continued confidence in growth momentum.</p><p>The strong results come amid accelerating Vault CRM adoption among top pharmaceutical companies. Biogen, Regeneron, and Eli Lilly have all committed to deploying the platform globally, bringing Veeva's commitments to 13 of the top 20 pharma companies versus six for Salesforce. Prior to the earnings release, Guggenheim and Stifel raised their price targets to $276 and $275 respectively, both maintaining Buy ratings.</p><p>(The above content is based on publicly available market information, generated by a program or algorithm, and is intended solely as a stock movement alert. It does not constitute investment advice or a basis for trading decisions.)</p></p>\n\n</article>\n</div>\n</body>\n</html>\n","isBrief":false,"type":0,"news_type":1,"symbol":"VEEV","symbol_name":"Veeva Systems Inc.","start_time":0,"source_url":"","article_id":"1187993950","we_media_id":"1054767329","thumbnails":[],"rights":null,"url":"https://stock-news.laohu8.com/highlight/detail?id=1187993950","pubTimestamp":1787775190,"columns":[],"sourceInfo":null,"weMediaInfo":{"media_name":"Market Focus","introduction":"Track stock‘s movements and relevant news","home_visible":1,"id":"1054767329","head_image":"https://static.tigerbbs.com/51943b2858f75e05ca2ebb144b4e626a"},"summary":"On August 27, Veeva rose 5.64% in after-hours trading, trading at $258.46/share, with turnover of $9.93 million.The company reported fiscal Q2 adjusted EPS of $2.35, beating the consensus estimate of...","collect":0,"end_time":0,"defaultTopTitle":"","property":[],"viewcount":null,"language":"en","relate_stocks":{"VEEV":"Veeva Systems Inc."},"translate_title":"走势警报|Veeva 盘后交易上涨 5.64%，第二季度盈利和收入超出预期，全年指引上调","themeId":null,"isJumpTheme":false,"ttsUrl":null,"symbols_score_info":{"VEEV":1},"content_text":"On August 27, Veeva rose 5.64% in after-hours trading, trading at $258.46/share, with turnover of $9.93 million.The company reported fiscal Q2 adjusted EPS of $2.35, beating the consensus estimate of $2.22 by 5.86% and representing an 18.09% year-over-year increase. Revenue came in at $927.96 million, surpassing the $905.28 million estimate. Additionally, Veeva raised its full-year fiscal 2027 adjusted EPS guidance to approximately $9.21, above the FactSet estimate of $9.06, reflecting continued confidence in growth momentum.The strong results come amid accelerating Vault CRM adoption among top pharmaceutical companies. Biogen, Regeneron, and Eli Lilly have all committed to deploying the platform globally, bringing Veeva's commitments to 13 of the top 20 pharma companies versus six for Salesforce. Prior to the earnings release, Guggenheim and Stifel raised their price targets to $276 and $275 respectively, both maintaining Buy ratings.(The above content is based on publicly available market information, generated by a program or algorithm, and is intended solely as a stock movement alert. It does not constitute investment advice or a basis for trading decisions.)","kind":"news","is_publish_news":true,"is_publish_highlight":false,"is_publish_live":false,"is_publish_wemedia":true,"editions":null,"column":"","sentiment":"1","news_tag":"dataReport","news_rank":0,"isVideo":false,"video":null,"symbols":[],"gpt_button":0,"need_auth":false,"need_login_tip":false,"code":"91000000","status":"200"}}}